Assessment of Efficacy and Safety of Tirofiban in Acute Coronary Syndrome Patients Following Percutaneous Coronary Intervention: A Prospective Observational Study

Open Access

Abstract

Background: Cardiovascular disease ranks as a top global cause of mortality, with acute coronary syndrome (ACS) necessitating urgent treatment like percutaneous coronary intervention (PCI) to lower complications. Glycoprotein IIb/IIIa inhibitors such as tirofiban efficiently avert thrombotic occurrences during PCI while maintaining a positive safety profile. Although there is international evidence, data from Bangladesh are scarce; this study assesses the effectiveness and safety of tirofiban in ACS patients receiving PCI in a Bangladeshi coronary care unit. Methods & Materials: This observational study at Khwaja Yunus Ali Medical College Hospital, Sirajganj, Bangladesh (Nov 2024–Oct 2025) assessed the effectiveness and safety of Inj. Tirofiban for ACS patients receiving PCI. Adult patients treated with Tirofiban were included, and data on demographics, risk factors, clinical presentation, angiography, stents, procedural results, and complications were gathered. Ethical clearance was secured, and data were examined descriptively with SPSS v26. Results: Among 120 ACS patients undergoing PCI with Inj. Tirofiban, primarily involved males between the age group of 50 and 59. Hypertension, smoking, and diabetes were the most prevalent risk factors, with NSTEMI and STEMI being the main manifestations. Angiographically, single-vessel disease was the most common. All procedures were successfully finished, with minor thrombus occurring in 2.7% of cases and resolved using tirofiban, while complications related to the procedure were minimal, restricted to 2.5% of minor gum bleeding. Conclusion: Tirofiban is both safe and effective for ACS patients receiving PCI, ensuring a high success rate in procedures, effective control of thrombus, and few complications.